![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhRnjvRGhY0OLhYwau_5gHFMV-_XxssgUiaha_EVpz0nomz2KvnGrRLufxkDjFQO_KEuhmDFCwmAKrsaWjIYqPUNTaqFuTyuO4vb-PCrT31GEsHeEgJ_U-fOyZy-6KV3QaKbQhEqf-1nC1B/s320/ngc_mast_word.jpg)
Guideline Title
Rituximab for the first-line treatment of chronic lymphocytic leukaemia.
Bibliographic Source(s)
National Institute for Health and Clinical Excellence (NICE). Rituximab for the first-line treatment of chronic lymphocytic leukaemia. London (UK): National Institute for Health and Clinical Excellence (NICE); 2009 Jul. 33 p. (Technology appraisal guidance; no. 174).
Guideline Status
This is the current release of the guideline.
full-text:
National Guideline Clearinghouse | Rituximab for the first-line treatment of chronic lymphocytic leukaemia.
No hay comentarios:
Publicar un comentario